Cytokinetics, Incorporated (CYTK) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Cytokinetics, Incorporated (CYTK) posted $88.04M in revenue for fiscal 2025 (up 376.6% year over year), with a net loss of $784.96M, and has compounded revenue about 9.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Cytokinetics, Incorporated
Cytokinetics, Incorporated has grown revenue from $106.41M to $88.04M over the last 10 fiscal years, compounding about 9.5% a year. The most recent year was up 376.6%, so growth is actually accelerating.
Net margin sits at -891.6%, up 2299.5 points year over year. It carries about $246.38M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Cytokinetics, Incorporated's SEC filings — descriptive, not advice. Ask the analyst your own question →
Cytokinetics, Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.41M | $13.37M | $31.50M | $26.87M | $55.83M | $70.43M | $94.59M | $7.53M | $18.47M | $88.04M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $16.45M | $-127.79M | $-106.29M | $-121.69M | $-127.29M | $-215.31M | $-388.95M | $-526.24M | $-589.53M | $-784.96M |
| Net margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
Source: Cytokinetics, Incorporated SEC filings (10-K). 27 years of history available in the interactive view.
Cytokinetics, Incorporated: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 45.0% over 4 years (84.8M → 122.9M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $328.7M of debt while last year's operating cash flow was negative ($-510M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -891.6%).
Explore 27 years of Cytokinetics, Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CYTK in your portfolio →
Cytokinetics, Incorporated financial history by metric
Compare Cytokinetics, Incorporated with peers
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated — frequently asked questions
What is Cytokinetics, Incorporated's revenue?
Cytokinetics, Incorporated (CYTK) reported revenue of $88.04M for fiscal year 2025, up 376.6% from the prior year, according to its SEC filings.
Is Cytokinetics, Incorporated profitable?
No — CYTK reported a net loss of $-784.96M in fiscal 2025.
What is CYTK's P/E ratio?
Cytokinetics, Incorporated trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Cytokinetics, Incorporated growing?
CYTK's revenue grew at roughly 9.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Cytokinetics, Incorporated have?
As of fiscal year 2025, CYTK carried roughly $246.38M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cytokinetics, Incorporated's market cap?
Cytokinetics, Incorporated (CYTK) has a market capitalization of about $9.08B, based on the latest data in our nightly-refreshed cache.
When does Cytokinetics, Incorporated's fiscal year end?
CYTK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Cytokinetics, Incorporated's official SEC filings (10-K and 10-Q), covering 27 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.